US 11180562
Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies
granted A61KA61K39/39533A61K47/6817
Quick answer
US patent 11180562 (Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies) held by CytomX Therapeutics, Inc. expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K39/39533, A61K47/6817, A61K47/6849